Pfizer steps up race for weight-loss drug

Pfizer steps up race for weight-loss drug

on Also in ,
Pfizer plans to discontinue its obesity drug lotiglipron and focus instead on its weight loss drug danuglipron as it races to rival the success of other weight loss treatments.

Share:

Previous
Next

Comentarios

Publicar un comentario

Leave a comment. Thanks!

Comentarios de Facebook

Suscribirse a: Enviar comentarios (Atom)